

MET Expression and Amplification in Patients with Localized Gastric Cancer

Yelena Y. Janjigian¹, Laura H. Tang², Daniel G. Coit³, David P. Kelsen¹, Todd D. Francone³, Martin R. Weiser³, Suresh C. Jhanwar², and Manish A. Shah¹

Abstract

Background: MET, the receptor for hepatocyte growth factor, has been proposed as a therapeutic target in gastric cancer. This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer.

Methods: Tumor specimens from patients enrolled on a preoperative chemotherapy study (NCI 5700) were examined for the presence of MET gene amplification by FISH, MET mRNA expression by quantitative PCR, MET overexpression by immunohistochemistry (IHC), and for evidence of MET pathway activation by phospho-MET (p-MET) IHC.

Results: Although high levels of MET protein and mRNA were commonly encountered (in 63% and 50% of resected tumor specimens, respectively), none of these tumors had MET gene amplification by FISH, and only 6.6% had evidence of MET tyrosine kinase activity by p-MET IHC.

Conclusions: In this cohort of patients with localized gastric cancer, the presence of high MET protein and RNA expression does not correlate with MET gene amplification or pathway activation, as evidenced by the absence of amplification by FISH and negative p-MET IHC analysis.

Impact: This article shows a lack of MET amplification and pathway activation in a cohort of 38 patients with localized gastric cancer, suggesting that MET-driven gastric cancers are relatively rare in Western patients. *Cancer Epidemiol Biomarkers Prev*; 20(5); 1021–27. ©2011 AACR.

Introduction

Despite a worldwide prevalence of nearly one million new cases annually (1), drug development in gastric cancer has lagged and the prognosis for patients with gastric cancer remains poor. Conventional therapy for metastatic gastric cancer remains palliative, with a median survival for metastatic disease of less than one year (2–4). New therapeutic targets for gastric cancer are needed.

Preclinical data suggest that the hepatocyte growth factor (HGF)/MET pathway may represent a therapeutic target for gastric adenocarcinoma (5). The MET proto-oncogene, located on the 7q31 locus, encodes the receptor tyrosine kinase MET, also known as the MET or HGF receptor (6, 7). The binding of HGF to its receptor, MET,

results in C-terminus receptor tyrosine phosphorylation and receptor activation. MET receptor targets include activation of the phosphoinositide 3-kinase-Akt/protein kinase B (PI3K-Akt), mitogen-activated protein kinase (MAPK), and phospholipase C γ pathways, all of which suppress apoptosis, promote tumor cell survival, gene transcription, angiogenesis, cellular proliferation, migration, mitosis, and differentiation (8). In tumors, MET oncogene dependence occurs when the MET tyrosine kinase becomes constitutively active, resulting in gain of function due to MET mutation [found in hereditary papillary renal carcinomas (9) and lung cancers (10)] or MET amplification [reported in gastric, esophageal (11), and lung cancers (12)]. MET mutations are exceedingly rare in gastric cancer (13–16).

Earlier reports describe MET amplification in approximately 20% of gastric tumors (17–21) and MET protein overexpression [assessed by immunohistochemistry (IHC)] in approximately 50% of advanced gastric cancers (22–24). MET amplification and overexpression may herald aggressive tumor biology and worse clinical outcome (8, 17, 22, 24). MET protein overexpression correlates with increased depth of tumor invasion and increased metastatic potential (23, 24). On the basis of evidence that MET dysregulation contributes to the growth and progression of gastric adenocarcinoma and that MET inhibition may be an attractive new target for the treatment of gastric

Authors' Affiliations: Departments of Medicine¹, Pathology², and Surgery³, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York

Note: Presented in part at 99th AACR Annual Meeting; April 12–16, 2008, San Diego, CA.

Corresponding Author: Yelena Y. Janjigian, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-8608; Fax: 212-717-3320. E-mail: janjigiy@mskcc.org

doi: 10.1158/1055-9965.EPI-10-1080

©2011 American Association for Cancer Research.

adenocarcinoma, this study was conducted to determine the incidence of *MET* expression and amplification in gastric cancer in a uniform population of U.S. patients with locally advanced gastric adenocarcinoma.

Materials and Methods

Patients and tissue samples

The Memorial Sloan-Kettering Institutional Review Board approved the study. All patients provided written informed consent for participation on National Cancer Institute-sponsored protocol of a preoperative chemotherapy study (NCI 5700) between June 2003 and November 2005. Thirty-eight patients provided tissue for *MET* assessment. Patient clinical characteristics included sex, age, histology, and pathologic stage.

FISH

FISH was conducted on formalin-fixed, paraffin-embedded tissues. DNA probes for *MET* (bacterial artificial chromosome clone RPC11-163C9; Invitrogen Life Technologies) and the centromere of chromosome 7 were directly labeled via nick translation with SpectrumRed (*MET*) and SpectrumGreen (centromere of chromosome 7) fluorophores, respectively. Slides were prepared by using standard cytogenetic techniques. The slides were denatured in 70% formamide/2× SSC for 5 minutes at 72°C and dehydrated in 70%, 85%, and 100% ethanol. The slides were then hybridized in 50% formamide, 2× SSC, Cot-1 DNA, and 50 ng of each probe at 37°C in a humid chamber overnight. After washing in 2× SSC/0.3% NP-40 at 72°C for 2 minutes, the slides were air-dried, counterstained with 0.2 μmol/L 4',6-diamidino-2-phenylindole (DAPI), and cover slipped. The signals were visualized with a Nikon Eclipse fluorescence microscope containing SpectrumRed (*MET* locus), SpectrumGreen (centromere), and DAPI filters (Nikon Instruments). A total of 200 interphase cells were analyzed from each sample. The Metasystem software (Digital Scientific) was used for capturing the images.

Quantitative PCR for analysis of *MET* RNA amplification

Quantitative PCR for analysis of *MET* genomic amplification primers and probes for *MET* and 18s rRNA were obtained from Applied Biosystems. Primer and probe sequences for *MET* were (5'-3'): F-GGAGCCAAAGT-CCTTTCATCTGTAA, RGCAATGGATGATCTGGGAA-ATAAGAAGAAT, and FAM-CCGTTTCATCAACTTC. Reactions were done in triplicate under standard thermocycling conditions by using 10 ng of genomic DNA, primers at 900 nmol/L, and probes at 250 nmol/L. Levels of expression of *MET* mRNA are reported as relative copies that are normalized against 18S rRNA expression (25).

IHC for *MET* and phospho-*MET* protein expression

All specimens were fixed in 10% phosphate-buffered formalin and embedded in paraffin. For each case, all

available hematoxylin and eosin-stained sections were reviewed, and a representative tissue block was selected for additional studies. Lauren classification was used to classify tumors according to histologic type. Standard ABC peroxidase techniques were used for IHC that was carried out on 4-μm paraffin sections of formalin-fixed, paraffin-embedded resected gastric cancer specimens. The following antibodies were used: anti-*MET* (C-12) from Santa Cruz Biotechnology and phospho-*MET* [(p-*MET*) Y1234/Y1235] from Cell Signaling Technology. A pathologist coded *MET* and p-*MET* expression as the percentage of positive tumor cells (scale 0%–100%) with staining intensity from 0 to 3+. Positive IHC expression is defined as 25% or more staining with intensity 2 or 3+. The reference pathologist (L.T.) reviewed all IHC *MET* and p-*MET* stains.

Statistical analysis

MET mRNA (PCR) and protein (IHC) expression was correlated with histology, tumor location, and treatment response by using the Fischer exact and Wilcoxon rank-sum tests.

Results

Table 1 shows clinical characteristics of the patients. The patient cohort consists predominantly of middle to distal stomach tumors (71%), with a similar number of patients with Lauren's diffuse (38%) and intestinal tumors (40%). Fifty-seven percent of the patients had

Table 1. Clinical characteristics of patients on study (N = 38)

Age at diagnosis, median (range)	59 (35–77)
Sex	
Women	15
Men	23
Median KPS	90%
Tumor location	
GEJ and proximal	9
Mid to distal stomach	29
Lauren classification	
Diffuse	15
Intestinal	17
Mixed	6
AJCC (5th edition 1998) stage at surgery	
0 ^a	1
I–II	17
IIIA/IIIB	14
IV (occult peritoneal disease)	7

Abbreviations: KPS, Karnofsky performance status; AJCC, American Joint Committee on Cancer.

^aOne cases with no residual tumor at surgery.

locally advanced stage III or IV (occult peritoneal disease) tumors.

FISH for *MET* amplification

FISH analysis of *MET* was successful in all 38 (100%) tumor specimens. Table 2 presents the fractions of cells with *MET*/CEP7 signal in each tumor specimen. The

presence of more than 2 gene-specific signals (red) accompanied by the same number of chromosome 7 centromere-specific signals (green) was regarded as indication of polysomy of chromosome 7 (CEP7; Fig. 1). Eleven (33%) tumors were polysomic for chromosome 7 and displayed equal numbers of copies of *MET* and CEP7 (range, 3–8 copies). Nine of these 11

Table 2. Analysis of the resected tumors for *MET* copy number (FISH), mRNA (PCR), *MET* protein expression (IHC), and phosphorylation status (p-*MET* IHC)

FISH copy ratio of <i>MET</i> /CEP7 (<i>n</i> = 38)	Relative <i>MET</i> mRNA expression (median 5.5, <i>n</i> = 14 ^a)	IHC	
		<i>MET</i> (<i>n</i> = 38)	p- <i>MET</i> (<i>n</i> = 30)
3 to 5/3 to 5		2+	0
2/2	9.9	1+	Luminal
2/2		1+	1+
2/2		2+	
2/2	14.4	1+	
2/2	11.4	2–3+	1+
2/2		1+	0
2/2	1.9	2+	0
2/2	3.1	2+ (10%)	Luminal
3/3		0	
2/2		2+	0
2/2		2+	1+
3 to 8/3 to 8	3.3	2+	2+
3 to 4/3 to 4 in 5% cells	34.2	2–3+	0
2/2		1+	1+
2/2	52.4	2+	0
2/2	2.3	2+	
2/2		2+	
3 to 4/3 to 4	5.2	2+	
2/2		2+	1+
2/2	14.4	2+	
3 to 6/3 to 6		2+	0
2/2	5.9	2+	0
2/2	2.1	1+	0
2/2	4.2	1+	0
3 to 4/3 to 4		2+	0
2/2		2+	1+ focal
3 to 5/3 to 5		1+	0
2/2		1+	
3 to 4/3 to 4 in 3% cells		2+	Luminal
2/2		1+	2+
2/2		2+	Luminal
3 to 5/3 to 5		2+	Luminal
2/2		2+	0
2/2		1+	1+
2/2		2+	1+ focal
2/2		1+	0
3 to 5/3 to 5		2+	0

^aIncludes only surgical specimens.




Figure 1. Representative interphase FISH analysis of a gastric tumor sample without *MET* amplification. The *MET* signal in red is associated with 8 individual copies of chromosome 7 centromere in green (polyploidy).

tumors had high *MET* IHC. *MET* amplification (defined as *MET*/CEP7 ratio > 2) was not identified in this sample set.

Table 2 summarizes individual tumor *MET* and p-*MET* IHC, *MET* mRNA PCR, and FISH results.

Quantitative PCR analysis for *MET* mRNA

Quantitative PCR was done in 15 tumor specimens and matched normal gastric mucosa. Relative *MET* mRNA expression was significantly higher for tumor than for normal (9.9 vs. 3.0, $P = 0.008$), and this was due to high relative *MET* mRNA expression in Lauren's intestinal histology versus normal ($P = 0.02$; Table 3).

Immunohistochemical analysis for *MET* and p-*MET* expression

Resected tumor specimens of 38 patients were examined by IHC for *MET*, and 30 specimens were tested by IHC for p-*MET*. Table 4 summarizes the tumor characteristics of patients in *MET* IHC-positive and -negative groups. Positive *MET* staining by IHC was associated with Lauren intestinal histology ($P = 0.006$). Five of 7 (71%) cases with high *MET* mRNA expression (above median) were noted to have high *MET* IHC (Fig. 2). Two of 30 (6.6%) gastric cancer specimens revealed positive staining for p-*MET* (Table 2, Fig. 3). Of these, one specimen was *MET* IHC positive without an increase in *MET* mRNA expression (Table 3).

The result summary is presented in Table 5. Although *MET* IHC positivity was relatively common, increased *MET* phosphorylation was rare and *MET* amplification was not seen.

Discussion

MET amplification is believed to occur frequently in gastric cancer (5, 26). Previous studies noted *MET* ampli-

Table 3. Relative *MET* mRNA expression by tumor histology

<i>n</i> = 15 ^a	Median	<i>P</i>
Tumor vs. normal	9.9 vs. 3.0	0.008
Lauren intestinal vs. normal	20 vs. 3.0	0.002
Lauren diffuse vs. normal	5.2 vs. 3.0	NS
Lauren mixed vs. normal	3.8 vs. 3.0	NS

^aIncludes analysis of endoscopic biopsies.

fication in up to 50% of gastric cancer cell lines (5, 17) and up to 20% of patients' gastric tumor samples (17–21). However, in this evaluation, we identified *MET* gene amplification in none of 38 locally advanced gastric adenocarcinomas that comprised the study set. We did observe 30% of gastric tumors with multiple *MET* gene copy numbers as a result of polysomy 7. It is known that breast tumors with an increased *HER2* gene copy number as a result of polysomy 17 behave as *HER2*-negative tumors (27). This phenomenon, therefore, suggests that gastric cancers with *MET* polysomy are unlikely to be *MET* driven.

The presence of *MET* amplification in prior studies (mostly from Japan) could possibly be linked to differences in tumor biology between Asian and Western patients. Distal stomach tumors are more common in Japan and have a favorable prognosis compared with proximal stomach and gastroesophageal junction (GEJ) tumors, which are more common in U.S. patients (5-year overall survival rates of approximately 60% vs. 20%; refs. 2, 4, 28–34). A recent study compared survival following resection of 2,357 Korean and U.S. patients. Even when evaluated by multivariate analysis, correcting for validated prognostic factors (35), Korean gastric cancer patients had improved survival over U.S. patients, suggesting that differences in tumor biology cannot be excluded (36). The distinct tumor biology of gastric cancer subtypes (37–40) and specific host genetic variations among ethnic groups (30, 41–43) might contribute to the difference in survival; although treatment approaches and mass screening programs in Japan also add to survival variability (44).

Another possible explanation for the discrepancy of our study with previous reports is that prior studies were conducted by using the Southern blot technique, which overestimated the incidence of *MET* amplification because it could not discriminate polysomy 7 from *MET* amplification. FISH methodology is technically more standardized and less affected by tissue variables, and it has replaced Southern blot in modern clinical diagnostic molecular pathology. In 1998, Hara and colleagues used FISH to examine 154 primary gastric tumors from Japanese patients and found that 6 (4%) tumors were *MET* amplified (45). It is likely that *MET* amplification does occur in gastric cancer but at a rate

Table 4. MET protein expression by IHC by tumor histology, location, and stage

<i>n</i> = 38	MET positive* (<i>n</i> = 24)	MET negative (<i>n</i> = 14)	<i>P</i>
Lauren classification, <i>n</i> (%)			
Diffuse or mixed	9 (28)	12 (86)	0.006
Intestinal	15 (63)	2 (14)	
Location, <i>n</i> (%)			
GEJ or proximal	8 (33)	4 (28)	NS
Mid to distal stomach	16 (66)	10 (71)	
Stage at surgery, <i>n</i> (%)			
I-II	10 (41)	6 (43)	NS
III-IV	14 (58)	8 (57)	

*MET positive defined as MET IHC intensity of ≥ 2 in $\geq 25\%$ of tumor cells.

substantially lower than that commonly reported in the literature.

Smolen and colleagues have shown that gastric cancer cell lines with high-level amplification of *MET* are extraordinarily susceptible to the selective MET tyrosine kinase inhibitor (TKI) PHA-665752. Treatment with MET TKI resulted in massive apoptosis in 5 of 5 *MET*-amplified (FISH) gastric cancer cell lines and none of the 12 *MET*-negative cell lines (5). With such a dramatic benefit in preclinical models of MET-driven gastric cancer, the success of MET-targeted therapy (31) in gastric cancer will depend on correctly selecting the patient population whose tumors depend on MET for growth and development.

In our analysis, MET protein and mRNA expression were commonly encountered (in 63% and 50% of resected tumor specimens, respectively) and are concordant with reported literature (23, 24, 46). The significance of the increase in *MET* expression on a transcriptional level is unclear, especially when considering the absence of *MET*




Figure 2. MET protein expression in gastric carcinoma by IHC. Positive MET immunoreactivity was identified in a moderately differentiated intestinal-type adenocarcinoma with cytoplasmic staining pattern (A). In contrast, MET reactivity was not observed in a poorly differentiated mucinous adenocarcinoma with signet ring cell features. Original magnification $\times 200$.




Figure 3. p-MET protein expression in gastric carcinoma by IHC. Positive p-MET immunoreactivity was shown in a portion of a moderately to poorly differentiated adenocarcinoma (A; bottom left) and was negative in other areas of the same tumor (top right). The staining pattern was membranous as well as cytoplasmic, although the immunoreactivity was not seen in all the cells (B). Original magnification $\times 100$ (A) and $\times 200$ (B).

amplification or MET tyrosine kinase activity. In breast cancer, multiple copies of chromosome 17 (location of the *HER2* gene) has been associated with increased HER2 oncoprotein staining by IHC, without *HER2* gene amplification (47).

In the absence of *MET* amplification, *MET* activation in gastric cancer might be related to deregulation of micro-RNA that is related to the *MET* gene as an alternative

Table 5. Results summary

	Positive	Negative
<i>MET</i> amplification by FISH (<i>n</i> = 38)	0	38
IHC		
<i>MET</i> (<i>n</i> = 38)	24	14
p-MET (<i>n</i> = 30)	2	28

pathway that is associated with aggressiveness of the gastric tumors. MicroRNAs are a class of small, noncoding RNAs that regulate gene expression, and they are increasingly implicated in the pathogenesis of cancer (48). Migliore and colleagues have shown that miR-34b, miR-34c, and miR-199a can decrease *MET* expression on the protein and RNA level and impair *MET*-mediated invasive growth in a gastric cell line that has *MET* amplification (49). Unique microRNA signatures are associated with different histologic subtypes, pattern of progression, and prognosis in gastric cancer (50). It is possible that certain microRNAs, the nature of which remains to be investigated, can increase *MET* protein expression (in the absence of *MET* gene amplification).

Our study shows the lack of *MET* amplification and pathway activation in Western patients with gastric cancer. In a separate study of unselected advanced gastric cancer patients, single-agent *MET* TKI (GSK1363089) failed to show antitumor activity (51). We conclude that *MET*-driven gastric cancers are rare

in the Western population. Future studies of *MET* inhibitors will, therefore, require better patient selection and trial design.

Disclosure of Potential Conflicts of Interest

M.A. Shah obtained a commercial research grant from GlaxoSmith Klein. Y.Y. Janjigian is a consultant/advisory board member of Roche/Genentech and obtained a commercial research grant from Boehringer-Ingelheim.

Grant Support

This study was sponsored in part by the DeGregorio Family Foundation for Gastric and Esophageal Cancer Research and ASCO Career Development Award (to M.A. Shah).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 13, 2010; revised January 6, 2011; accepted February 24, 2011; published OnlineFirst March 10, 2011.

References

- Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. *Lancet*. 2009;374:477–90.
- Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006;24:2137–50.
- Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlander N, et al., editors. SEER Cancer Statistics Review, 1975–2006. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
- Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of *MET* may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. *Proc Natl Acad Sci U S A* 2006;103:2316–21.
- Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science* 1991;251:802–4.
- Galland F, Stefanova M, Lafage M, Birnbaum D. Localization of the 5' end of the MCF2 oncogene to human chromosome 15q15-q23. *Cytogenet Cell Genet* 1992;60:114–6.
- Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. *Met*, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003;4:915–25.
- Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the *MET* proto-oncogene in papillary renal carcinomas. *Nat Genet* 1997;16:68–73.
- Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. *Cancer Res* 2003;63:6272–81.
- Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al. Genomic amplification of *MET* with boundaries within fragile site FRA7G and upregulation of *MET* pathways in esophageal adenocarcinoma. *Oncogene* 2006;25:409–18.
- Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhi R, Garraway L, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. *Cancer Res* 2005;65:5561–70.
- Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. *Biochem Biophys Res Commun* 2010;394:1042–6.
- Chen JD, Kearns S, Porter T, Richards FM, Maher ER, Teh BT. *MET* mutation and familial gastric cancer. *J Med Genet* 2001;38:E26.
- Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al. A novel germ line juxtamembrane *Met* mutation in human gastric cancer. *Oncogene* 2000;19:4947–53.
- Kim IJ, Park JH, Kang HC, Shin Y, Lim SB, Ku JL, et al. A novel germline mutation in the *MET* extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. *J Med Genet* 2003;40:e97.
- Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. *Biochem Biophys Res Commun* 1992;189:227–32.
- Seruca R, Suijkerbuijk RF, Gartner F, Criado B, Veiga I, Olde-Weghuis D, et al. Increasing levels of MYC and *MET* co-amplification during tumor progression of a case of gastric cancer. *Cancer Genet Cytogenet* 1995;82:140–5.
- Tsujimoto H, Sugihara H, Hagiwara A, Hattori T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. *Virchows Arch* 1997;431:383–9.
- Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, *MET*, *WNT2*, and *ERBB2*. *Genes Chromosomes Cancer* 1998;23:307–16.
- Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. *Genes Chromosomes Cancer* 1999;24:299–305.
- Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. *Cancer* 1999;85:1894–902.
- Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma—correlation to clinical features. *Acta Oncol* 2001;40:638–43.
- Amemiya H, Kono K, Itakura J, Feng Tang R, Takahashi A, An FQ, et al. c-Met expression in gastric cancer with liver metastasis. *Oncology* 2002;63:286–96.

25. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. *Cancer Lett* 2007;248:219–28.
26. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. *Mol Cancer Ther* 2008;7:3499–508.
27. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens M-R, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. *J Clin Oncol* 2008;26:4869–74.
28. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute;2005.
29. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. *J Gastrointestinal Surg* 2005;9:718–25.
30. Faycal J, Bessaguet C, Nousbaum JB, Cauvin JM, Cholet F, Bideau K, et al. Epidemiology and long-term survival of gastric carcinoma in the French district of Finistère between 1984 and 1995. *Gastroenterol Clin Biol* 2005;29:23–32.
31. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. *Clin Cancer Res* 2009;15:2207–14.
32. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA* 1991;265:1287–9.
33. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Nat Cancer Inst* 1998;90:150–5.
34. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. *Gastroenterology* 1993;104:510–3.
35. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. *J Clin Oncol* 2003;21:3647–50.
36. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. *Ann Surg* 2010;251:640–6.
37. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. *Cancer Res* 2003;63:3309–16.
38. Dent DM. Cancer surgery: why some survival benefits may be artefactual. *Br J Surg* 1998;85:433–4.
39. Shiu MH, Moore E, Sanders M, Huvos A, Freedman B, Goodbold J, et al. Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. *Arch Surg* 1987;122:1347–51.
40. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. *Br J Surg* 1993;80:1015–8.
41. Steinberg ML, Hwang BJ, Tang L, Shah MA. E-cadherin gene alterations in gastric cancers in different ethnic populations. *Ethn Dis* 2008;18 Suppl 2:S2-70–4.
42. Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, et al. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. *J Hum Genet* 2008;53:479–89.
43. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. Interleukin-10-1082 promoter polymorphism associated with gastric cancer among Asians. *Eur J Cancer* 2008;44:2648–54.
44. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with *Helicobacter pylori* seropositivity. *J Nat Cancer Inst* 2006;98:1445–52.
45. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence *in situ* hybridization. *Lab Invest* 1998;78:1143–53.
46. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. *Cancer* 1999;85:1894–902.
47. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. *J Mol Diagn* 2003;5:155–9.
48. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. *Cell* 2003;113:673–6.
49. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al. MicroRNAs impair MET-mediated invasive growth. *Cancer Res* 2008;68:10128–36.
50. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. *Gastric Cancer* 2006;9:203–7.
51. Jhaver M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. *J Clin Oncol* 27:15s, 2009 Suppl: 4502. Abstract 4502.